Ivosidenib-azacitidine in acute myeloid leukemia with IDH1 R132 mutation

被引：0
|
作者：
Mechelfekh, Yaquine [1 ]
Gastaud, Lauris [2 ]
机构：
[1] Univ Angers, CHU Angers, Lab Hematol, Angers, France
[2] Ctr Antoine Lacassagne, Serv Oncohematol, Nice, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 12期
关键词：
VENETOCLAX;
D O I：
10.1016/j.bulcan.2023.08.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1232 / 1233
页数：2
相关论文
共 50 条
  • [21] Acute Myeloid Leukemia With IDH1 or IDH2 Mutation Frequency and Clinicopathologic Features
    Patel, Keyur P.
    Ravandi, Farhad
    Ma, Deqin
    Paladugu, Abhaya
    Barkoh, Bedia A.
    Medeiros, L. Jeffrey
    Luthra, Rajyalakshmi
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 135 (01) : 35 - 45
  • [22] R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes
    Kawakami, Shota
    Ochiai, Kazuhiko
    Azakami, Daigo
    Kato, Yuiko
    Michishita, Masaki
    Morimatsu, Masami
    Ishiguro-Oonuma, Toshina
    Onozawa, Eri
    Watanabe, Masami
    Omi, Toshinori
    VETERINARY RESEARCH COMMUNICATIONS, 2018, 42 (01) : 49 - 56
  • [23] Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype
    Salem, Dalia
    Abd El-Aziz, Sherin
    El-Menshawy, Nadia
    Abouzeid, Tarek
    Ebrahim, Mohamed
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 49 - 55
  • [24] Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
    Trovarelli, Giulia
    Sbaraglia, Marta
    Angelini, Andrea
    Bellan, Elena
    Pala, Elisa
    Belluzzi, Elisa
    Pozzuoli, Assunta
    Borga, Chiara
    Dei Tos, Angelo Paolo
    Ruggieri, Pietro
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2024, 482 (06) : 947 - 956
  • [25] AGILE: Ivosidenib plus azacitidine versus placebo plus azacitidine in patients with newly diagnosed AML with an IDH1 mutation
    Murthy, Vidhya
    Dohner, Harmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Heuser, Michael
    Recher, Christian
    De Botton, Stephane
    Hui, Jianan
    Gianolio, Diego
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 7 - 7
  • [26] Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype
    Dalia Salem
    Sherin Abd El-Aziz
    Nadia El-Menshawy
    Tarek Abouzeid
    Mohamed Ebrahim
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 49 - 55
  • [27] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Doehner, Hartmut
    Martinelli, Giovanni
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du
    Wang, Xiwei
    Gong, Jing
    Kapsalis, Stephanie M.
    Hickman, Denice
    Zhang, Vickie
    Winkler, Thomas
    Daigle, Scott
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
  • [28] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] IDH1 p.S280F Mutation Is Potentially a Novel Mechanism of Resistance to Ivosidenib Therapy in an IDH1-Positive Acute Myeloid Leukemia
    Oltvai, Z. N.
    Koes, D.
    Meredith, M.
    Warlick, E. D.
    Nelson, A. C.
    Yohe, S.
    Mroz, P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1143 - 1143
  • [30] AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
    Stein, Eytan
    Dinardo, Courtney Denton
    Jang, Jun Ho
    Miyazaki, Yasushi
    Martinez, Roberto Ovilla
    Auer, Julia
    Zhang, Vickie
    Koralek, Daniel O.
    Wu, Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345